8-K 1 bfnh0115098k.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  January 15, 2009

 


BioForce Nanosciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

  

         

Nevada

 

000-51074

 

74-3078125

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

1615 Golden Aspen Drive, Suite 101

Ames, Iowa 50010

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (515) 233-8333

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[  ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[  ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[  ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 

Section 7 - Regulation FD


Item 7.01  Regulation FD Disclosure.

Beginning in January 2009, our management will make presentations to investors using the slide presentation attached to this report on Form 8-K as Exhibit 99.1.

The slide presentation contained in the exhibit includes statements intended as "forward-looking statements," which are subject to the cautionary statement about forward-looking statements set forth in the exhibit.  The information contained in this Item 7.01 and the attached Exhibit 99.1 is furnished to, but not filed with, the Securities and Exchange Commission.  The information contained herein and in the accompanying exhibit shall not be incorporated by reference to any of our filings, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing.  The filing of this current report on Form 8-K is not an admission or determination as to the materiality or completeness of any information in this Item 7.01 or the attached Exhibit 99.1


Section 9 - Financial Statements and Exhibits


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.

Description

99.1

Presentation dated January 2009




-2-





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

BioForce Nanosciences Holdings, Inc.


By:

/s/ Gregory D. Brown

 

Gregory D. Brown

 

Chief Financial Officer

   

Date:  January 15, 2009

 




INDEX TO EXHIBITS

 

Exhibit No.

Description

99.1

Presentation dated January 2009





-3-